Kornimate/medical-research-clean huggingface dataset:
efficacy of continuous sciatic nerve block in diabetic foot patients

Conditions: Diabetic Foot; Regional Anesthesia; Catheter Blockage; Wound Heal

Summary: patients who underwent surgery for diabetic foot were divided into three groups: sciatic nerve block (group b), continuous nerve catheter (group c) . group b patients underwent preoperative popliteal ultrasound guided peripheral nerve blockage. 20 ml of 0.25% bupivacaine was administered. in group c patients, 20% bupivacaine 20 ml was applied to the sciatic nerve with a peripheral nerve catheter and continuous infusion was started with patient controlled analgesia device.

ethics committee approval was received on 12 december 2019, numbered 19/344. the study was planned to include 90 adult patients undergoing diabetic foot surgery at gülhane training and research hospital between 12 december 2019 and february 2020. these patients were divided into three groups: sciatic nerve block (group b), continuous nerve catheter (group c). group b patients underwent preoperative popliteal ultrasound guided peripheral nerve blockage. 20 ml of 0.25% bupivacaine was administered. in group c patients, 20% bupivacaine 20 ml was applied to the sciatic nerve with a peripheral nerve catheter and continuous infusion was started with patient controlled analgesia device. preoperative and postoperative blood flow of the popliteal and tibialis posterior arteries, pain scores of patients were evaluated with numeric rating scale and wound healing was monitored and recorded. the differences between the groups were compared statistically.

Eligibility criteria:
inclusion criteria: * undergoing diabetic foot surgery * spending the first postoperative night hospitalized * age 40 years or older exclusion criteria: * inability to communicate with the investigators and hospital staff * incarceration * clinical neuropathy in the surgical extremity

Keywords: diabetic foot sciatic nerve catheter wound heal
a translational study of tumor antigen-pulsed dc vaccine for escc

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed dc vaccine( ocdc and neodc) for postoperative adjuvant treatment of escc


Eligibility criteria:
inclusion criteria: * pathologically confirmed diagnosis of esophageal squamous cell carcinoma * no preoperative adjuvant therapy * karnofsky performance status 0-2; * the postoperative pathological stage is pt2-4 and / or n + m0 according to ajcc 8th * function of the main organs is normal; * edition patient's written informed consent exclusion criteria: * tumor emergencies; * abnormal coagulation function; * contagious diseases, such as hiv, hbv, hcv infection; * mental disorders; * concomitant tumors; * immunological co-morbidities

Keywords: esophageal cancer tumour cell lysate neoantigen prime-boost dendritic cell vaccine
a phase ib study of lxh254-centric combinations in nsclc or melanoma

Conditions: Non-Small Cell Lung Cancer; Melanoma

Summary: to characterize safety and tolerability and identify a recommended dose and regimen for the lxh254 in combination with ltt462 or trametinib or ribociclib.


Eligibility criteria:
inclusion criteria: * patients must have advanced or metastatic nsclc or cutaneous melanoma * presence of kras or braf mutation (nsclc) or nras mutation (cutaneous melanoma) in tumor tissue * all patients participating in this clinical trial must have progressed following standard therapy or, in the opinion of the investigator, no effective standard therapy exists, is tolerated, appropriate or is considered equivalent to study treatment. * ecog (eastern cooperative oncology group) performance status ≤ 2 exclusion criteria: -dose expansion - kras or nras mutant patients groups: prior treatment with a rafi (including any brafi and pan-rafi), meki and/or erki. (patients with kras mutant nsclc with prior g12c inhibitor treatments are also excluded in the lxh254+trametinib expansion part). braf mutant patients group: prior treatment with any egfr, alk, ros1, kras, raf (both brafv600 selective and pan-raf), mek1/2 and/or erk1/2 inhibitors (for patients with braf v600 mutant nsclc, prior treatments with braf and mek1/2 inhibitors are allowed). patients who have received more than 3 lines of anti-cancer therapy are excluded. * history or current evidence of retinal vein occlusion (rvo) or current risk factors for rvo. * any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. * patients receiving proton pump inhibitors (ppi) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study. * patients with gilbert's syndrome or other heritable diseases of bile processing. other protocol-defined inclusion/exclusion criteria may apply

Keywords: nsclc melanoma nras kras braf lxh254 ltt462 trametinib ribocliclib non-small cell lung carcinoma (nsclc) treatment of lung cancer after first metastasis lung cancer lung adenocarcinoma large-cell lung carcinoma non small cell lung carcinoma non small cell lung cancer large cell lung carcinoma large cell lung cancer squamous cell lung carcinoma
childhood migraine treatment noninvasive pulsed radiofrequency vs flunarizine

Conditions: Migraine Disease

Summary: the aim of this observational study was to investigate the long-term effects of patients receiving interventional transcutaneous electrode-pulsed radiofrequency therapy versus calcium channel blockers for the treatment of childhood migraine pain. the main question to be answered was. which of the long-term effects of interventional transcutaneous pulsed radiofrequency versus calcium channel blockers for the treatment of childhood migraine pain is more effective? participants who have started both treatments will answer questions about their headaches in an online survey for 3 months as part of their regular medical care.

there are two groups in the trial. one group will receive transcutaneous pulsed radiofrequency treatment for a total of 3 weekly sessions. the other group will receive 1x 5 mg flunarizine active ingredient. both groups will consist of 30 patients. all patients will be followed from the start of treatment and will be assessed at month 1 and month 3 using the paediatric migraine disability index, headache diaries and visual pain scale.

Eligibility criteria:
inclusion criteria: * diagnosed with migraine according to ichd-3 migraine criteria * being between the ages of 8-18 * having 4 or more migraine attacks per month exclusion criteria: * other primary or secondary headache diagnosis * patient could not be reached during follow-up
early systolic notching in pulmonary embolism

Conditions: Pulmonary Embolism

Summary: venous thromboembolism (vte), clinically seen as deep vein thrombosis (dvt) or pulmonary embolism (pe), is the third most common acute cardiovascular syndrome after myocardial infarction and stroke. in a study conducted by critical care and emergency physicians, lung ultrasonography (us) for pleural infarction areas, lower extremity venous us in terms of dvt, and focused cardiac us in terms of right ventricular strain were demonstrated with different diagnostic values for pe. however, no ultrasonographic method alone has a high diagnostic value for pe alone in the literature. in a recent study, it is stated that a new cardiac finding (early systolic notch- esn) has high sensitivity (92%) and specificity (99%) in massive and submassive emboli. however, the limited patient population and the exclusion of many patient groups limits the applicability of the study and its use in other patient groups. with this study, it was aimed to determine the diagnostic value of esn finding within the emergency department conditions by keeping the patient population wider.


Eligibility criteria:
inclusion criteria: * patients undergoing pulmonary ct angiography with suspicion of pulmonary embolism exclusion criteria: * pregnant women, * patients under 18 years of age, * those who received thrombolytic therapy, * poor ultrasound imaging.
evaluation of the contribution of transoral robotic-assisted surgery using da vinci xi for head and neck tumors

Conditions: Head and Neck Cancer

Summary: head and neck cancers are treated either with surgical resection followed by adjuvant radiotherapy, or with organ preservation strategies using definitive radiotherapy with or without concomitant chemotherapy. these treatments have long-time functional side effects and consequences on the quality of life. transoral robotic surgery has been developing since 2006 by weinstein and o'malley in alternative to open surgery, to decrease the morbidity of the large surgical approach. the da vinci device had the fda approval and the ce mark in 2009 for transoral surgery of head and neck cancers, using previous generations of da vinci. the last generation da vinci xi has received the fda approval for laparoscopic surgery in april 2014 and the ce mark in june 2014 but has not been evaluated yet in transoral surgery. the objective of our study is therefore to study the feasibility of this transoral robotic surgery for head and neck cancers, using the da vinci xi.


Eligibility criteria:
inclusion criteria: 1. patient \>/= 18 2. who status 0-2 3. ent cancer or solid tumor histologically proven regardless histology 4. all maps of the head and neck and any stage 5. surgically resectable according to clinical examination and preoperative investigations, confirmed in multidisciplinary meeting 6. treatment: * first-line * or after induction chemotherapy * or local recurrence regardless of the previous treatment * or second location in irradiated 7. transoral exposition of tumor, assessed preoperatively during endoscopy during the balance of extension of the lesion 8. the patient must have accepted the possibility of surgical conversion open surgery 9. the patient must have been clearly informed of the study and have formulated his non-opposition to participate exclusion criteria: 1. metastasis (s) clinical or radiological remote, inaccessible (s) to a local curative treatment 2. post-treatment tumor progression and / or early recurrence \< 3 months 3. unresectable tumor by robotic transorally: bone infiltration, deep infiltration of soft tissues, unresectable lymphadenopathy 4. contraindications to the suspension for transoral tumor exposure: dental fragility against-indication for cervical extension 5. pathology against intercurrent-indicating cancer surgery 6. pregnancy 7. inability to submit to medical monitoring study for geographical, social or psychological.
sleep apnea in elderly male twins

Conditions: Lung Diseases; Sleep Apnea Syndromes; Obesity

Summary: to conduct a genetic analysis of anatomic risk factors for sleep apnea in a well-characterized united states population-based registry of elderly male twins who have been successfully followed for the past 30 years.

background: the contribution of genetic factors to sleep disorders has been demonstrated in twin and family studies, and further understanding of the genetic underpinning of sleep disorders is considered an important area of research. many of the suggested risk factors for sleep apnea (e.g.,craniofacial morphology, obesity) have genetic determinants. however, a formal genetic analysis of these anatomical risk factors with sleep-recorded physiological measurements has not so far been conducted. design narrative: the investigators recruited a subsample of pairs from the nas-nrc world war ii twin registry in which at least one of the twin brothers reported sleep apnea symptoms and a subsample of control pairs in which both twins reported no symptoms. they monitoring the subgroup of twin pairs with overnight sleep recording. they also collected anthropometric measurements of weight, height, neck circumference, and craniofacial morphology and blood samples for determination of zygosity and dna extraction for future molecular studies. the twin design is most powerful for estimating the genetic and/or environmental overlap between physiological measurements such as sleep-recorded disordered breathing, obesity, and craniofacial morphology. the investigators chose to focus on an elderly male twin sample for which a wealth of data relevant to this study had been previously collected. twin pair concordance or discordance for monitored sleep-disordered breathing allowed the full characterization of genetic/familial and individual environmental factors associated with the expression and severity of this condition. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
post market trust - u.s.a. study

Conditions: Symptomatic Uterine Fibroids

Summary: this post market study is being conducted to compare the direct and indirect cost of three approaches (gfa, myomectomy, and uterine artery embolization) for the treatment of symptomatic uterine fibroids. in addition, data from this study is being used to satisfy the requirements of the united states food and drug administration's 522 (post market surveillance) order.

the purpose of this study is to 1) evaluate the economic burden, safety and outcomes of three uterine-conserving treatment alternatives for symptomatic uterine fibroids: myomectomy, uterine artery embolization (uae), and global fibroid ablation (gfa) using the acessa™ system, and 2) meet the requirements of the u.s. food and drug administration's 522 order for post market surveillance in this study, subjects who have symptomatic uterine fibroids will be randomized to one of three uterine-conserving treatments based on the local standard of care.

Eligibility criteria:
inclusion criteria: * are ≥ 18 years old and menstruating * have symptomatic uterine fibroids * have a uterine size ≤ 16 gestational weeks as determined by pelvic exam * have all fibroids that are less than 10 cm in any diameter * desire uterine conservation * have had a normal pap smear within the past 36 months defined as "no untreated cervical malignancy or dysplasia." * are willing and able to comply with all study tests, procedures, and assessment tools * are capable of providing informed consent. exclusion criteria: * have contraindications for laparoscopic surgery and/or general anesthesia. * are expected to be high risk for, or are known to have, significant intra-abdominal adhesions (defined as adhesions that would require extensive dissection to mobilize and view all surfaces of the uterus) * patients requiring major elective concomitant procedures (e.g., hernia repair) * are pregnant or lactating * have taken any depot gonadotropin releasing hormone (gnrh) agonist within three months prior to the screening procedures * have an implanted intrauterine or fallopian tube device for contraception that cannot or will not be removed at least 10 days prior to treatment * have chronic pelvic pain known to not be due to uterine fibroids * have known or suspected endometriosis stage 3 or 4, adenomyosis * have active or history of pelvic inflammatory disease * have a history of, or evidence of, gynecologic malignancy or pre-malignancy within the past five years * have had pelvic radiation * have a non-uterine pelvic mass over 3 cm * have a cervical myoma * have one or more completely intracavitary submucous fibroids (type 0) or only type 0/1 submucous fibroids that are better treated via hysteroscopic methods * in the medical judgment of the investigator should not participate in the study * are not willing to be randomized to treatment.

Keywords: fibroids myomas leiomyomata menorrhagia acessa procedure radiofrequency ablation (rfa) gfa acessa
recurrence of rotator cuff lesion after surgical repair with single-row vs double-row suture bridge tecnique: a comparative study

Conditions: Cuff Injury, Rotator

Summary: the rotator cuff is a muscle-tendon complex consisting of the tendons of the supraspinatus, subspinatus, subscapularis, and small round muscles capable of allowing movement of the shoulder joint in the various planes of space and stabilizing the glenohumeral joint. rotator cuff tendon injuries are very common. in most cases, these injuries are mostly degenerative based, as they are related to the aging process of the individual. however, it is increasingly common to diagnose such injuries in young individuals as well. the reported incidence of rotator cuff injuries ranges from 5% to 40%, and of course the prevalence increases with age until it reaches 51% in patients older than 80 years. the diagnosis of rotator cuff injury is made based on clinical examination and instrumental investigations such as nuclear magnetic resonance imaging (mri). rotator cuff repair involves the use of anchors with included suture threads that allow the tendons to be returned to the level of the anatomical insertion, called the footprint. suture technique varies depending on the extent of injury and tendon and bone quality. single-row (single row) or double-row suture bridge (double-row suture bridge) anchoring techniques are currently a hotly debated topic in the literature.


Eligibility criteria:
inclusion criteria: * patients aged ≥45 years with a diagnosis of full-thickness rotator cuff injury \<2cm * arthroscopic rotator cuff repair surgery with single row or double row suture bridge * follow-up \> 24 months * completeness of clinical-radiographic documentation * patients at first rotator cuff repair surgery on affected side exclusion criteria: * patients with associated injuries to the affected upper limb * patients with neuromuscular disorders, or established psychomotor disorders * patients with associated injuries of the subscapularis muscle tendon * patients with a history of previous surgery of the affected shoulder * patients with massive rotator cuff injury \> 2cm * patients with severe pathologies of other organs or apparatuses that limit competitive or recreational sports activities * pregnant women * patients who cannot undergo high-field mri (pcs with cochlear implants, cardiac, vascular or osteoarticular magnetic, pcs with previous gunshot wounds)
smartphone based tele-rehabilitation on functional capacity and sleep quality among coronary heart disease patients.

Conditions: Coronary Heart Disease

Summary: to determine the effectiveness of smartphone based tele-rehabilitation on functional capacity and sleep quality among coronary heart disease patients.


Eligibility criteria:
inclusion criteria: * both male \& female * age 20-69 years * participants should have a documented diagnosis of cad, confirmed by a medical professional. * individuals with a history of myocardial infarction (heart attack), angina, or evidence of significant coronary artery stenosis. * stable cad who are not experiencing acute coronary events, such as recent heart attacks or unstable angina. exclusion criteria: * acute illness * uncontrolled hypertension * uncontrolled metabolic disease * bone fracture in the last 6 months * neurological diseases that limit the ability to ambulate or stand from a chair * msk disease * severe cardiovascular complications such as heart failure with reduced ejection fraction, severe arrhythmias. * patients with unstable conditions or cardiac episodes. * ejection fraction \< 40%
steroid injection for adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: this study was conducted to compare the efficacy of hydrodilatation with low dose steroid with high dose steroid for treating adhesive capsulitis.

design: a prospective, double-blinded, randomized, clinical trial patient and methods: patients with adhesive capsulitis for at least 3 months were enrolled and randomly allocated into group 1 (hydrodilatation with low dose steroid ) and group 2 (hydrodilatation with high dose steroid). the patients were evaluated before treatment and were reevaluated 0, 6, and 12 weeks after the beginning of the treatment. outcomes measures included a pain scale (visual analog scale), range of motion, constant shoulder score, shoulder pain and disability index

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of adhesive capsulitis 2. a duration of complaints more than 3 months 3. a reduction in passive range of motion in at least 2 of the following: forward flexion, abduction, or external rotation of the affected shoulder of more than 30 degree compared with the other side. exclusion criteria: 1. prior manipulation of the affected shoulder under anesthesia; 2. other conditions involving the shoulder ( rheumatoid arthritis, hill-sachs lesions, osteoarthritis, damage to the glenohumeral cartilage,osteoporosis, or malignancies in the shoulder region); 3. neurologic deficits affecting shoulder function in normal daily activities; 4. shoulder pain caused by cervical radiculopathy 5. a history of drug allergy to hyaluronic acid; 6. pregnancy or lactation; 7. received injection into the affected shoulder during the preceding 3 months
feasibility and safety study of nivolumab with irinotecan for small cell lung cancer

Conditions: Small-cell Lung Cancer; Small Cell Lung Carcinoma

Summary: this study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (sclc) when given nivolumab and irinotecan together followed by nivolumab maintenance. this study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer.


Eligibility criteria:
inclusion criteria: * confirmed sclc with known ugt1a genotype. * patients who have received at least 1 prior platinum-based chemotherapy. * life expectancy of 3 months or more. * measurable disease. exclusion criteria: * patients with ugt1a polymorphism. * currently receiving chemotherapy. * pregnant and nursing women.

Keywords: lung cancer relapsed lung cancer